Cargando…

Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction

Background: Clinical guidelines recommend beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers, and statins for the secondary prevention of acute myocardial infarction (AMI). It is not clear whether variation in real-world practice reflects poor quality-of-care or a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schroeder, Mary C., Chapman, Cole G., Chrischilles, Elizabeth A., Wilwert, June, Schneider, Kathleen M., Robinson, Jennifer G., Brooks, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680510/ https://www.ncbi.nlm.nih.gov/pubmed/36412823 http://dx.doi.org/10.3390/pharmacy10060147

Ejemplares similares

Field methods in medical record abstraction: assessing the properties of comparative effectiveness estimates
por: Cook, Elizabeth A, et al.
Publicado: (2014)

Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?
por: Brooks, John M., et al.
Publicado: (2018)

Use of Statins by Medicare Beneficiaries Post Myocardial Infarction: Poor Physician Quality or Patient-Centered Care?
por: Schroeder, Mary C., et al.
Publicado: (2015)

Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction
por: Solomon, Matthew D., et al.
Publicado: (2020)

Guidelines for experimental models of myocardial ischemia and infarction
por: Lindsey, Merry L., et al.
Publicado: (2018)

Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction
por: Jortveit, Jarle, et al.
Publicado: (2022)

Long-term secondary prevention of acute myocardial infarction (SEPAT) – guidelines adherence and outcome
por: Ergatoudes, Constantinos, et al.
Publicado: (2016)

Acute myocardial infarction secondary to COVID-19 infection: A case report and review of the literature
por: Capaccione, Kathleen M., et al.
Publicado: (2021)

Trends in the Use of Guideline-Recommended Medications and In-Hospital Mortality of Patients with Acute Myocardial Infarction in a Chinese Population
por: Hu, Jing, et al.
Publicado: (2015)

Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction
por: Arnold, Suzanne V., et al.
Publicado: (2020)

Pharmacological Treatment Following Myocardial Infarction: How Large Is the Gap Between Guideline Recommendations and Routine Clinical Care?
por: Schupp, Tobias, et al.
Publicado: (2021)

Use of recommended medications after myocardial infarction in Austria
por: Winkelmayer, Wolfgang C., et al.
Publicado: (2007)

Repetitive Myocardial Infarctions Secondary to Delirium Tremens
por: Schwartzberg, David, et al.
Publicado: (2014)

Acute Myocardial Infarction Secondary to Paradoxical Embolism
por: Alenezi, Abdullah R, et al.
Publicado: (2020)

Thrombin Generation in the Glasgow Myocardial Infarction Study
por: Smid, Machiel, et al.
Publicado: (2013)

Effect of implementing an acute myocardial infarction guideline on quality indicators
por: Makdisse, Marcia, et al.
Publicado: (2013)

Acute myocardial infarction secondary to mucormycosis after lung transplantation
por: Naik, Chetan A., et al.
Publicado: (2020)

SBC Guidelines on Unstable Angina and Non-ST-Elevation Myocardial Infarction: Executive Summary
por: Feitosa-Filho, Gilson Soares, et al.
Publicado: (2015)

Secondary Prevention of Myocardial Infarction in People Living With HIV Infection
por: Erqou, Sebhat, et al.
Publicado: (2020)

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION SECONDARY TO COVID-19
por: DOUEDI, STEVEN, et al.
Publicado: (2021)

Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors
por: Sundbøll, Jens, et al.
Publicado: (2022)

Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (“Jena auf Ziel”)
por: Makhmudova, Umidakhon, et al.
Publicado: (2023)

Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction
por: Joshi, Nikhil V, et al.
Publicado: (2015)

Adherence to recommendations for secondary prevention medications after myocardial infarction in Estonia: comparison of real-world data from 2004 to 2005 and 2017 to 2018
por: Lõiveke, Piret, et al.
Publicado: (2021)

Randomised controlled trial of a secondary prevention program for myocardial infarction patients ('ProActive Heart'): study protocol. Secondary prevention program for myocardial infarction patients
por: Hawkes, Anna L, et al.
Publicado: (2009)

Use of Guideline-Directed Medical Therapy in Patients With ST-Elevation Myocardial Infarction
por: Latifi, Ahmad Nawid, et al.
Publicado: (2020)

Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic
por: Gao, Jing, et al.
Publicado: (2022)

Canadian National Guidelines and Recommendations for Integrating Career Advising Into Medical School Curricula
por: Howse, Kelly, et al.
Publicado: (2017)

Characteristics and Outcomes of Early Recurrent Myocardial Infarction After Acute Myocardial Infarction
por: Nair, Raunak, et al.
Publicado: (2021)

Heart‐Brain Team Approach of Acute Myocardial Infarction Complicating Acute Stroke: Characteristics of Guideline‐Recommended Coronary Revascularization and Antithrombotic Therapy and Cardiovascular and Bleeding Outcomes
por: Suzuki, Toshiaki, et al.
Publicado: (2023)

Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode
por: Keating, Dolores, et al.
Publicado: (2017)

Secondary Prevention of Myocardial Infarction With Nonpharmacologic Strategies in a Medicaid Cohort
por: Oberg, Erica B., et al.
Publicado: (2009)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Non-ST elevation myocardial infarction secondary to carbon monoxide intoxication
por: Jankowska, Danuta, et al.
Publicado: (2017)

Going beyond the mean: economic benefits of myocardial infarction secondary prevention
por: von Wyl, Viktor, et al.
Publicado: (2020)

Mechanical Complication of Acute Myocardial Infarction Secondary to COVID-19 Disease
por: Damluji, Abdulla A., et al.
Publicado: (2022)

Mechanical Complication of Acute Myocardial Infarction Secondary to COVID-19 Disease
por: Damluji, Abdulla A., et al.
Publicado: (2023)

Markers of thrombin generation are associated with myocardial necrosis and left ventricular impairment in patients with ST-elevation myocardial infarction
por: Hansen, C. H., et al.
Publicado: (2015)

Increased Mortality among Survivors of Myocardial Infarction with Kidney Dysfunction: the Contribution of Gaps in the use of Guideline-Based Therapies
por: Peterson, Pamela N, et al.
Publicado: (2009)

Dietary Guidelines for Americans, 2020–2025: Understanding the Scientific Process, Guidelines, and Key Recommendations
por: Snetselaar, Linda G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hs5u5bb4gimea0abvulbmsruv4